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Background: Lymphoceles are a common complication after pelvic lymphadenectomy in women with
gynecologic malignancies. Although typically asymptomatic, lymphoceles can superinfect requiring medical or
surgical intervention. A single center randomized controlled trial provided first evidence, that a collagen-fibrin patch
(Tachosil®) is effective in the prevention of symptomatic lymphoceles after pelvic lymphadenectomy.
Methods/Design: We will perform a multicentre, blinded, randomized, controlled trial comprising 140 women with
gynecologic malignancies undergoing pelvic lymphadenectomy. Women will be randomly allocated to Tachosil®
application or no application. Primary outcome is efficacy, defined as lymphocele CTCAE 4.03 grade ≥2 within four
weeks after surgery. Secondary outcomes are asymptomatic lymphocele verified by ultrasound, medical or surgical
intervention. Assuming a two-sided 5% significance level, a power of 80%, and a drop out rate of 10%, a sample size
of 68 patients per group was calculated to detect a 66% absolute decrease in symptomatic lymphoceles.
Discussion: We aim to provide further evidence for the efficacy of a collagen-fibrin patch in the prevention of
symptomatic lymphoceles in women with gynecological malignancies undergoing pelvic lymphadenectomy.
Trial registration: This study is registered at ClinicalTrials.gov (NCT01470677, protocol ID: TACHO-1). This study is
registered at the EudraCT database (EudraCT number: 2011-003115-34).
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Women with gynecologic malignancies such as cervical
and endometrial cancer routinely undergo pelvic lymph-
adenectomy based on tumor characteristics assessed prior
to or during surgery. Pelvic lymphadenectomy may be
performed by open surgery or laparoscopy [1-4]. The rate
of intraoperative complications during and after laparo-
scopic and open pelvic lymph node dissection is generally* Correspondence: christoph.grimm@meduniwien.ac.at
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unless otherwise stated.low, but has potential long-term consequences such as
lower extremity lymph edema, nerve injury, and chronic
pain. O’Hanian et al., for example, describe an intraopera-
tive complication rate of 7% in a series of 30 patients with
pelvic and paraaortic lymphadenectomy [1]. In a series of
257 women with cervical cancer undergoing laparoscopic-
ally assisted radical trachelectomy and pelvic lymphade-
nectomy, Marchiole et al. describe 11 (4%) intraoperative
complications with 5 (2%) of these attributable to lymph-
adenectomy, i.e. vascular and ureteral injury [2]. Xu et al.
performed laparoscopic pelvic lymphadenectomies in 313
patients with cervical cancer, 143 of which also underwent
paraaortic lymphadenectomy and report 7 (2%) cases ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nectomy [3]. Postoperative complications during and after
pelvic lymphadenectomy include local abscess, bleeding,
lymphocele, and chronic lymphedema of the lower ex-
tremities, which has an incidence of 1 to 2% [2,3]. The rate
of complications does not seem to differ significantly in
women undergoing open or laparoscopic lymphadenec-
tomy based on the available literature [1-6].
In the present trial, we will focus on pelvic lymphoceles,
one of the most common complications of pelvic lymphad-
enectomy. Simonato et al. described a rate of 19/30 (63%)
of sonographically detected lymphoceles in men undergo-
ing pelvic extraperitoneal lymphadenectomy for prostate
cancer [4]. In this trial, 4/19 men with lymphoceles were
symptomatic and required medical interventions. In
women with cervical cancer, asymptomatic lymphoceles
detected by ultrasound have been noted in up to 11% of
women after pelvic lymphadenectomy [1,3,5]. In 2% of
women, clinical symptoms will require a therapeutic
intervention [6].
Tachosil® is a fibrin-collagen coated patch and has been
licensed in 2004 in Europe for surgical use in humans to
support surgical hemostatic interventions. The efficacy
and safety of Tachosil® has been demonstrated in liver re-
section, pulmonary lobectomy, and kidney tumor resec-
tion trials [7-9]. In men, but not in women, it has been
demonstrated that the application of a collagen-fibrin
patch to the lymphadenectomy surgery site may prevent a
significant proportion of lymphoceles. In a randomized
trial, Simonato et al. found that the pelvic application of
two Tachosil® patches to the obturator fossa and the fem-
oral canal was sufficient to significantly reduce the rate of
sonographically detected lymphoceles within 4 weeks after
surgery from 19/30 to 5/30 cases (p = 0.001) as well as the
mean drainage volume from 190 to 64 ml. Percutaneous
puncture of a symptomatic lymphocele was necessary in
1/30 individuals in the intervention group compared to
4/30 individuals in the control group [4]. In women with
gynecological malignancies a single center randomized
controlled trial has found, that Tachosil® seems effective to
reduce the rate of lymphoceles after pelvic lymphadenec-
tomy [5]. 7/30 (23.3%) women in the treatment group
compared to 9/28 (57.7%) women in the control group
developed asymptomatic lymphoceles (p < 0.05) [5]. No
significant differences between the two groups were ob-
served in the development of symptomatic lymphoceles
or the rate of interventions [5]. This may be attributable
to the small sample size of this study. As symptomatic
lymphoceles are more relevant for the patient, it seems
clinically more important to evaluate the impact of
Tachosil® on the rate of symptomatic lymphoceles after
pelvic lymphadenectomy.
Symptomatic lymphoceles are defined by the CTCAE
4.03 grading system as lymphoceles grade ≥2. This includesall lymphoceles needing medical intervention. Thus this
definition comprises, lymphoceles with the presence of
localized pelvic pain, pelvic abscess, fever, and/or leg
edema in the presence of a sonographically verified pel-
vic lymphocele.
In summary, the data available in the literature demon-
strate that pelvic lymphoceles occur in 11 to 63% of indi-
viduals undergoing pelvic lymphadenectomy. Symptomatic
lymphoceles seem to occur in about 32% of patients under-
going pelvic lymphadenectomy. Intraoperative application
of a collagen-fibrin patch may reduce the number of lym-
phoceles, mean drainage volume, and the necessity of med-
ical interventions such as percutaneous puncture.
Therefore, we intend to perform a multi center ran-
domized clinical trial assessing the efficacy of a collagen-
fibrin patch for preventing symptomatic lymphoceles in
women undergoing pelvic lymphadenectomy for gyneco-
logic malignancies, ie cervical and endometrial cancer.
We hypothesize that, based on the data of Simonato et al.
and Tinelli et al., the application of a collagen-fibrin patch
(Tachosil®) will reduce the number of symptomatic pelvic
lymphoceles by at least 66%.
Methods/Design
Aim of the study
Primary outcome variable:
2.1.1. To evaluate the incidence of symptomatic pelvic
lymphoceles defined by CTCAE 4.03 grade ≥2 within
4 weeks after surgery in women undergoing open or
laparoscopic pelvic lymphadenectomy for cervical and
endometrial cancer with and without the application of
Tachosil® during surgery.
Secondary outcome variables:
2.1.2 To evaluate the incidence of sonographically de-
tected pelvic lymphoceles of at least 2 cm in the largest
diameter 4 weeks after surgery in women undergoing
open or laparoscopic pelvic lymphadenectomy for cer-
vical and endometrial cancer with and without the appli-
cation of Tachosil® during surgery.
2.1.3. To evaluate the rate and type of medical in-
terventions for clinically symptomatic pelvic lympho-
celes such as analgesics and/or lymphocele puncture
and drainage.
2.1.4. To evaluate the rate of total and symptomatic
lymphoceles between the three centers.
2.1.5. To evaluate the rate of total and symptomatic
lymphoceles between cervical and endometrial cancer
patients.
2.1.6. To evaluate the rate of total and symptomatic
lymphoceles between the surgical device used for pelvic
lymphadenectomy.
2.1.7. To evaluate the rate of total and symptomatic
lymphoceles between patients with and without lymph
node metastases.
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lymphoceles depending on the total number of pelvic
lymph nodes removed.
2.1.9. To evaluate the rate of total and symptomatic
lymphoceles between patients with open and laparoscopic
pelvic lymphadenectomy.
Study hypothesis
We hypothesize that the intraoperative application of
two collagen-fibrin patches (Tachosil®) to the obturator
fossa and the femoral canal will reduce the number of
symptomatic pelvic lymphoceles by at least 66% (pri-
mary study end point).
Study design
Prospective randomized clinical intervention trial of 140
women undergoing open or laparoscopic pelvic lymphade-
nectomy for cervical or endometrial cancer. Randomization
will be by a computerized randomization list. Women will
be centrally randomized by the principal investigator (CT).
Allocation will be communicated by telephone after in-
formed consent has been obtained and after lymphade-
nectomy has been completed. This is a single-blinded
study, ie patients, but not surgeons, will be blinded to
the treatment allocation. Outcome assessment will not
be performed by the surgeon, who has performed the
lymphadenectomy. Outcome assessors will be blinded
to the treatment allocation.
Inclusion criteria
– Women undergoing open or laparoscopic surgery
for cervical or endometrial cancer.
– Age between 18 and 70 yrs.
– Informed consent.
Exclusion criteria
– Women with previously diagnosed lymph edema.
– Known disease of the lymphatic system.
– Immunocompromised women such as those with an
immunosuppressive medication or a known disease
of the immune system.
Treatment
All women will undergo open or laparoscopic surgery.
Within this procedure, as deemed appropriate by the
surgeon, women will undergo pelvic lymphadenectomy.
The procedure will be performed as follows:
The peritoneum will be incised parallel to the iliac
vessels. Then, the iliac vessels will be screened for the
presence of bulky lymph nodes. If a lymph node debulk-
ing is performed, no patch will be applied. In women
who undergo routine pelvic lymphadenectomy, lymphnode tissue will be removed from the external iliac ves-
sels, the obturator fossa, the interiliac region, and the
common iliac region after identification and appropriate
preparation of surgical landmarks, ie iliac vessels, femoral
canal, chorda, and obturator nerve. At the end of the pro-
cedure, hemostasis will be checked. A Tachosil® patch of
4.8x4.8 cm will be attached to the obturator fossa and a
Tachosil® patch of 4.8x4.8 cm will be attached to the fem-
oral canal of each side of surgery in the intervention group
(Figures 1, 2 and 3). In the control group, no Tachosil®
patch will be used. No specific drainage of the retroperito-
neum will be performed. The study team members
Clemens Tempfer, David Cibula, and Alexander Reinthaller,
experienced in open and laparoscopic pelvic lymph node
dissection, will perform all surgical procedures. In order to
ensure adequate application of the Tachosil® patch by
laparoscopy, all surgeons will perform at least two
laparoscopic training operations during which they
roll the Tachosil® patch around a laparoscopic instrument,
move it through a 10 mm trocar into the abdomen, and
flatten it out.
Patients have to agree to participate in the study and
sign informed consent at least one day before surgery. If
patients are eligible and agreed to participate, they are
included in consecutive order. Patients receive an enve-
lope according to their inclusion number in which allo-
cation is documented. This envelope accompanies the
patient into the operating room. A nurse opens the enve-
lope not before pelvic lymphadenectomy and hemostasis
have been completely finished. According to the treatment
group the patient is allocated, the surgeon now has to
apply either two Tachosil® patches in the intervention
group or no Tachosil® in the control group. Therefore, the
surgeon cannot influence the extent of the lymphadenec-
tomy, as he is not aware of the patient’s allocation until
the end of the lymphadenectomy.
Study population
The study population consists of 140 women undergoing
pelvic lymphadenectomy for cervical and endometrial can-
cer in one of the three study sites, ie the Departments of
Obstetrics and Gynecology at the Ruhr University Bochum,
the Gynecologic Oncology Center at the Charles University
in Prague, and the Medical University of Vienna fulfilling
the inclusion/exclusion criteria requirements.
Outcome variables
2.8.1. The incidence of symptomatic pelvic lymphoceles
CTCAE 4.03 grade ≥2 within 4 weeks after surgery in
women undergoing open or laparoscopic pelvic lymph-
adenectomy for cervical or endometrial cancer (primary
outcome variable).
2.8.2. The incidence of sonographically detected pelvic
lymphoceles of at least 2 cm in the largest diameter
Figure 1 Right pelvic side wall after systematic pelvic lymphadenectomy. 1 = Right external iliac artery. 2 = Right internal iliac artery,
3 = Right obturator nerve.
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laparoscopic pelvic lymphadenectomy for cervical and
endometrial cancer with and without the application of
Tachosil® during surgery (secondary outcome variable).
2.8.3. The rate and type of medical interventions for
clinically symptomatic pelvic lymphoceles such as anal-
gesics and/or lymphocele puncture and drainage (sec-
ondary outcome variable).
2.8.4. The length of hospital stay (secondary outcome
variable).Figure 2 Tachosil® is applied with a wet glove and sponge and compre2.8.5. The rate of predefined complications, ie abscess
in the pelvis, fever >38°C on at least two occasions >24 hrs
apart, leg swelling, local pelvic bleeding complications
necessitating a surgical intervention (secondary out-
come variable).
Statistical analysis
A power calculation demonstrated that, with a sample
size of 70 per group, a two-arm study has a power of
80% to detect a 66% absolute difference in treatmentssion for 30–60 seconds. Thereafter glove and sponge are removed.
Figure 3 Placement of the first Tachosil patch in the right obturator fossa. 1 = Right external iliac artery. 2 = Right internal iliac artery.
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mary outcome parameter, ie symptomatic lymphoceles
CTCAE 4.03 grade ≥2. This calculation was based on
published data by Tinelli et al. observing a rate of 32%
of symptomatic lymphoceles in the placebo group and
10% in the Tachosil® group [5]. Assuming a 10% drop
out-rate, 140 women will be randomized. The chi-square
test will used for comparisons of frequencies and cross-
tabulations. One Way ANOVA on ranks will be used on
means. Descriptive statistics (means, standard deviations,
and ranges) will be used for demographic data. Bonfer-
roni’s correction will be used for multiple comparisons
of secondary outcomes.
Risk benefit assessment
The expected rate of intraoperative and postoperative
complications following the study-based additional inter-
vention, i.e. application of two patches of Tachosil®, will
be minimal based on published studies [4-9]. For example,
Simonato et al. and Tinelli et al. reported no complication
associated with the use of Tachosil® patches [4,5]. How-
ever, local infectious complications, pain, and abscess
cannot be ruled out. A patient insurance for all participat-
ing women will be contracted covering all eventual harm
caused by study participation. Also, the duration of the
surgical intervention will not be increased due to the study
intervention in a relevant manner [4,5].
Women recruited for this study may eventually benefit
from participating since a previous randomized trial in
men undergoing pelvic lymphadenectomy has resulted
in a significant benefit of Tachosil® regarding occurrence
of lymphoceles and lymphocele drainage volume. Also,the number of medical interventions such as percutaneous
punctures may be reduced in the intervention group.
The putative findings of our study could help to modify
one step of the surgical technique of pelvic lymphadenec-
tomy, one of the most common gynecologic oncology
surgical procedures.
The present study has been approved the Ethics Com-
mittee of the Medical University of Vienna, Austria by
September 9th, 2011 (EC no.: 740/2011), of the Charles
University in Prague, Czech Republic by March 15th, 2012
(EC no.: cj459/12), and of the Marienhospital Bochum,
Germany by August 24th, 2012 (EC no.: 4299–12 FF).
Follow-up
All women will undergo a gynecologic examination and
a transvaginal and transabdominal ultrasound examin-
ation at the time of discharge of the hospital, performed
by a physician experienced in transvaginal and transab-
dominal ultrasound examinations, who has not partici-
pated in the original surgical procedure and is blinded
to the treatment allocation. All women will be sched-
uled for a follow-up visit 4 weeks after surgery includ-
ing a gynecologic examination and a transvaginal and
transabdominal ultrasound examination, performed by
a physician experienced in transvaginal and transab-
dominal ultrasound examinations, who has not partici-
pated in the original surgical procedure and is blinded
to the treatment allocation.
Data management and safety
Patients will be pseudo-anonymized for protection of
data privacy. At the time of inclusion, a code based on
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will be assigned to every patient. The code will only be
used for data entry in the database, as the patient’s full
name is not documented in the same database, where
clinical information is collected and stored. During the
clinical routine and follow-up visits patient information
is documented on study documents, where both, patient’s
full name and patient’s code, have to be documented. Only
the principal investigators (CT, DC, and AR) will have ac-
cess to study data.
Discussion
The present randomized, controlled trial aims to evaluate
the efficacy of Tachosil® in the prevention of symptomatic
lymphoceles after pelvic lymphadenectomy in gynaeco-
logical malignancies. This is a clinical relevant topic as
along with lymphedema, symptomatic lymphoceles are
the major complication after pelvic lymphadenectomy. Re-
cently, a study in patients with endometrial cancer de-
scribed a prevalence of 23% for lymphedema after pelvic
lymphadenectomy [10]. Due to the importance of this
topic a prospective trial led by the Gynecologic Oncology
Group has been released (GOG 244, GOG LEG study,
The Lymphedema and Gynecologic Cancer Study).
In contrast to lymphedema, which is rather a chronic
problem after pelvic lymphadenectomy, lymphoceles are
more of an acute complication. The prevalence of lym-
phoceles after pelvic lymphadenectomy provided in the lit-
erature varies quite substantially between 11-63% [4,5].
Symptomatic lymphoceles seem to occur in about 32% of
patients undergoing pelvic lymphadenectomy [5]. This
variation might be caused by numerous factors: the time
interval between surgery and follow-up visit for lympho-
celes as most of the small lymphoceles will spontaneously
regress over time, rather small study populations in the
majority of trials, the extent of lymphadenectomy, the use
of new energy sources [5,11]. Another interesting factor
possibly influencing the rate of lymphoceles after pelvic
lymphadenectomy might be the surgical approach. One
study revealed a postoperative lymphocele rate of 15.4%
and 1.4% in women after laparoscopic and after open
pelvic lymphadenectomy, respectively [12]. Of note, this
study retrospectively compared 138 women, who under-
went systematic laparoscopic pelvic lymphadenectomy,
to 123 historical control subjects, who underwent sys-
tematic pelvic lymphadenectomy via an open approach.
Due to the design, this study has to be interpreted with
caution [12]. In the present study, we aim to prospectively
describe the lymphocele rates following open compared
to laparoscopic systematic pelvic lymphadenectomy in
women with gynecological malignancy.
The value of Tachosil® in the prevention of lymphoceles
after pelvic lymphadenectomy in women has already been
studied in two clinical trials [5,13]. In a retrospectivematched case–control study, a cohort of 26 patients re-
ceiving Tachosil® after laparoscopic pelvic lymphadenec-
tomy was compared to a historical cohort of 29 women
without Tachosil® after laparoscopic pelvic lymphadenec-
tomy. The study described a significant difference in the
prevalence of total lymphoceles (19.2% of patients in the
Tachosil® group vs. 51.7% in the historical control group)
and a non-significant difference of symptomatic lympho-
celes (7.6% of patients in the Tachosil® group vs. 17.2% in
the historical control group). Of note, this was not a pro-
spective trial with a limited number of patients [13]. The
second study was a prospective randomized controlled
trial comprising 58 women with endometrial cancer
after undergoing pelvic lymphadenectomy with or with-
out Tachosil® [5]. This trial observed, that Tachosil®
seems effective to reduce the rate of lymphoceles after
pelvic lymphadenectomy [5]. 7/30 (23.3%) women in the
treatment group compared to 9/28 (57.7%) women in
the control group developed asymptomatic lymphoceles
(p < 0.05) [5]. No significant differences between the two
groups were observed in the development of symptomatic
lymphoceles or the rate of interventions [5]. This may be
attributable to the small sample size of this study.
As symptomatic lymphoceles are more relevant for the
patient, it seems clinically more important to evaluate
the impact of Tachosil® on the rate of symptomatic lym-
phoceles after pelvic lymphadenectomy. Therefore, we in-
tend to perform a multi center randomized clinical trial
assessing the efficacy of a collagen-fibrin patch for pre-
venting symptomatic lymphoceles in women undergoing
pelvic lymphadenectomy for gynecologic malignancies,
ie cervical and endometrial cancer. We hypothesize that
based on the data of Simonato et al. and Tinelli et al.,
the application of a collagen-fibrin patch (Tachosil®) will
reduce the number of symptomatic pelvic lymphoceles
by at least 66%.Conclusion
Despite being one of the major complications of lymph-
adenectomy, little is known about the prevention of
lymphoceles. One prospective controlled trial compris-
ing 58 women already evaluated the preventative effect
of Tachosil® in the prevalence of lymphoceles (5). As this
trial was not adequately powered to detect differences be-
tween symptomatic lymphoceles, we designed the present
open, randomized, controlled trial.Abbreviations
MD: Medical doctor; CTCAE: Common terminology criteria for adverse
events; C: Celsius; Hrs: hours.Competing interests
All authors declare that they have no competing interests.
Grimm et al. BMC Cancer 2014, 14:635 Page 7 of 7
http://www.biomedcentral.com/1471-2407/14/635Authors’ contributions
CG, DC, AR, and CT were crucially involved in the study design. CG and SP
were responsible for statistical analysis and performed sample size
calculations. SH and MZ were crucially involved in critical review of the study
design and timing and setting of follow-up visits. CG, DC, and CT were
mainly involved in drafting the study protocol. CG, CT, MZ, and SP helped in
coordinating the clinical trial. All authors critically reviewed the study
protocol and were contributed to the final version of the study protocol. All
authors read and approved the final manuscript.
Acknowledgements
We thank Takeda Pharmaceutical Company Limited for providing the study
medication, i.e., the collagen-fibrin patches (Tachosil®) for all participating
patients. No other funding has been provided by Takeda Pharmaceutical
Company Limited. The study has not been funded by an additional grant
and thus has not undergone a peer-review process by a funding body.
Author details
1Department of General Gynecology and Gynecologic Oncology,
Comprehensive Cancer Center - Gynecologic Cancer Unit, Medical University
of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. 2Department of
Obstetrics and Gynecology, Gynecologic Oncology Center, Charles University
in Prague, Prague, Czech Republic. 3Department of Obstetrics and
Gynecology, Ruhr University Bochum, Bochum, Germany.
Received: 9 January 2014 Accepted: 22 August 2014
Published: 30 August 2014
References
1. O’Hanlan KA, Pinto RA, O’Holleran M: Total laparoscopic hysterectomy
with and without lymph node dissection for uterine neoplasia.
J Minim Invasive Gynecol 2007, 14:449–452.
2. Marchiole P, Benchaib M, Buenerd A, Lazlo E, Dargent D, Mathevet P:
Oncological safety of laparoscopic-assisted vaginal radical trachelectomy
(LARVT or Dargent’s operation): a comparative study with
laparoscopic-assisted vaginal radical hysterectomy (LARVH).
Gynecol Oncol 2007, 106:132–141.
3. Xu H, Chen Y, Li Y, Zhang Q, Wang D, Liang Z: Complications of
laparoscopic radical hysterectomy and lymphadenectomy for invasive
cervical cancer: experience based on 317 procedures. Surg Endosc 2007,
21:960–964.
4. Simonato A, Varca V, Esposito M, Venzano F, Carmignani G: The use of a
surgical patch in the prevention of lymphoceles after extraperitoneal
pelvic lymphadenectomy for prostate cancer: a randomized prospective
pilot study. J Urol 2009, 182:2285–2290.
5. Tinelli A, Giorda G, Manca C, Pellegrino M, Prudenzano R, Guido M,
Dell’Edera D, Malvasi A: Prevention of lymphocele in female pelvic
lymphadenectomy by a collagen patch coated with the human
coagulation factors: a pilot study. J Surg Oncol 2012, 105:835–840.
6. Benedetti Panici P, Plotti F, Zullo MA, Muzii L, Manci N, Palaia I, Ruggiero A,
Angioli R: Pelvic lymphadenectomy for cervical carcinoma: Laparotomy,
extraperitoneal, transperitoneal or laparoscopic approach? A randomized
study. Gynecol Oncol 2006, 103:859–864.
7. Frilling A, Stavrou GA, Mischinger HJ: Effectiveness of a new carrier-bound
fibrin sealant versus argon beamer as haemostatic agent during liver
resection: a randomised prospective trial. Langenbecks Arch Surg 2005,
390:114–120.
8. Anegg U, Lindenmann J, Matzi V: Efficiency of fleecebound sealing
(TachoSil) of air leaks in lung surgery: a prospective randomised trial.
Eur J Cardiothorac Surg 2007, 25:198–202.
9. Siemer S, Lahme S, Altziebler S: Efficacy and safety of Tachosil as
hemostatic treatment versus standard suturing in kidney tumor
resection: a randomised prospective study. Eur Urol 2007, 52:1156–1163.
10. Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA, McGree ME,
Weaver AL, Dowdy SC: Lymphedema after surgery for endometrial
cancer: prevalence, risk factors, and quality of life. Obstet Gynecol 2014,
124:307–315.
11. Nezhat F, Yadav J, Rahaman J, Gretz H 3rd, Gardner GJ, Cohen CJ:
Laparoscopic lymphadenectomy for gynecologic malignancies using
ultrasonically activated shears: analysis of first 100 cases. Gynecol Oncol
2005, 97:813–819.12. Ghezzi F, Uccella S, Cromi A, Bogani G, Robba C, Serati M, Bolis P:
Lymphoceles, lymphorrhea, and lymphedema after laparoscopic and
open endometrial cancer staging. Ann Surg Oncol 2012, 19:259–267.
13. Tinelli A, Mynbaev OA, Tsin DA, Giorda G, Malvasi A, Guido M, Nezhat FR:
Lymphocele prevention after pelvic laparoscopic lymphadenectomy by
a collagen patch coated with human coagulation factors: a matched
case–control study. Int J Gynecol Cancer 2013, 23:956–963.
doi:10.1186/1471-2407-14-635
Cite this article as: Grimm et al.: A collagen-fibrin patch (Tachosil®) for the
prevention of symptomatic lymphoceles after pelvic lymphadenectomy in
women with gynecologic malignancies: a randomized clinical trial.
BMC Cancer 2014 14:635.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
